Ellomay Capital LTD (ELLO) Dividend History

Ellomay Capital Ltd. is an Israeli renewable energy and infrastructure company that develops, owns, and operates solar and wind power projects primarily in Europe. Established to capitalize on the growth in renewable energy, the company focuses on generating sustainable electricity and contributing to green energy initiatives across multiple markets.

Dividend History

Pay Date Amount Ex Dividend Date Record Date
April 20, 2016 $0.22 04/04/2016 04/06/2016

Company News

  • Ellomay Capital plans to raise approximately NIS 50 million through a private placement of 926,000 ordinary shares to Israeli institutional investors, with Menora Mivtachim Holdings expected to become an interested party holding about 6% of outstanding shares.

    GlobeNewswire Inc.
  • U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping over 100 points on Wednesday. The Dow traded down 0.34% to 32,929.04 while the NASDAQ fell 0.30% to 12,978.20. The S&P 500, also fell, dropping, 0.39% to 4,189.27. Check This Out: Top 5 Tech And Telecom Stocks That Are Flying - And May Collapse   Leading and Lagging Sectors Utilities shares rose by 0.7% on Wednesday. Meanwhile, top gainers in the sector included Ellomay Capital Ltd. (NYSE: ELLO), up 8%, and Star Group, L.P. (NYSE: SGU), up 4%. In trading on Wednesday, energy shares dipped 1.8%.   Top Headline Shares of Donaldson Co Inc (NYSE: DCI) dropped over 7% on Wednesday after the company reported third-quarter financial results and updated guidance. Donaldson reported a sales increase of 2.6% Y/Y to $875.7 million beating the consensus of $868.4 million. EPS stood at 76 cents, up from 67 cents a year ago, exceeding the consensus of $0.74. The company now expects FY23 adjusted EPS to be $3.00-$3.06 (vs $2.99-$3.07 previously) compared to the consensus of $3.04.   Equities Trading UP Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) shares shot up 116% to $0.3991 after the company announced it received agreement from the FDA on its proposed single confirmatory Phase 3 study of AR-301 and the clinical study design. Shares of Marker Therapeutics, Inc. (NASDAQ: MRKR) got a ...

    Benzinga
    Featured Companies: AAP DCI MRKR SGU VTGN
Page data last updated 07/23/2025 17:49:58 UTC